These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 4039870

  • 1. Comparative biological activities of whole cell pertussis vaccine and a new acellular preparation.
    García-Sánz JA, Ruiz-Puente J, Jiménez-Paredes J, González-Pacheco M, Villalva-Posada H.
    Vaccine; 1985 Mar; 3(1):23-6. PubMed ID: 4039870
    [Abstract] [Full Text] [Related]

  • 2. Comparative toxicity, protective, histamine sensitizing and leucocytosis promoting activities in mice of Bordetella pertussis culture fluid, bacterial cells and cell extracts.
    Megret F, Fournier JM, Alouf JE.
    Med Microbiol Immunol; 1984 Mar; 173(4):225-32. PubMed ID: 6096686
    [Abstract] [Full Text] [Related]

  • 3. A novel bivalent acellular pertussis vaccine based on the 69 kDa protein and FHA.
    Novotny P, Chubb AP, Cownley K, Charles IG.
    Dev Biol Stand; 1991 Mar; 73():243-9. PubMed ID: 1778316
    [Abstract] [Full Text] [Related]

  • 4. Production of a safe, potent and immunogenic partially purified acellular pertussis vaccine using simple indigenous techniques.
    Gupta RK, Saxena SN, Sharma SB, Ahuja S.
    Dev Biol Stand; 1991 Mar; 73():205-22. PubMed ID: 1778314
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Comparison of the protective effects of the pertussis acellular vaccine with the component vaccine, which have different amounts of fimbriae, against the experimental aerosol infection of mice with Bordetella pertussis.
    Morokuma K, Ginnaga A, Nishihara T, Tsunoda S, Furukawa M, Aihara K, Sakoh M.
    Dev Biol Stand; 1991 Mar; 73():223-32. PubMed ID: 1685713
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model.
    Kwon HJ, Han SB, Kim BR, Kang KR, Huh DH, Choi GS, Ahn DH, Kang JH.
    BMC Infect Dis; 2017 Apr 04; 17(1):247. PubMed ID: 28376777
    [Abstract] [Full Text] [Related]

  • 9. Further contributions to an improved pertussis vaccine: II. New findings in the development of a pertussis vaccine.
    Robbel L, Hungerer KD, Aktories K.
    Behring Inst Mitt; 1984 Nov 04; (76):110-2. PubMed ID: 6098261
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.
    Greco D, Salmaso S, Mastrantonio P, Giuliano M, Tozzi AE, Anemona A, Ciofi degli Atti ML, Giammanco A, Panei P, Blackwelder WC, Klein DL, Wassilak SG.
    N Engl J Med; 1996 Feb 08; 334(6):341-8. PubMed ID: 8538704
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. DNA vaccine encoding pertussis toxin S1 subunit induces protection against Bordetella pertussis in mice.
    Kamachi K, Konda T, Arakawa Y.
    Vaccine; 2003 Nov 07; 21(31):4609-15. PubMed ID: 14575775
    [Abstract] [Full Text] [Related]

  • 14. Development and clinical testing of an acellular pertussis vaccine containing genetically detoxified pertussis toxin.
    Rappuoli R, Pizza M, De Magistris MT, Podda A, Bugnoli M, Manetti R, Nencioni L.
    Immunobiology; 1992 Feb 07; 184(2-3):230-9. PubMed ID: 1587545
    [Abstract] [Full Text] [Related]

  • 15. Potency assay and characterization of lymphocytosis promoting factor in whole cell and acellular pertussis vaccines.
    Tiru M, Falk A, Brym-Grynblat B, Pettersson IM.
    Dev Biol Stand; 1991 Feb 07; 73():157-65. PubMed ID: 1778309
    [Abstract] [Full Text] [Related]

  • 16. Engineering bacterial toxin for the development of new vaccine against pertussis.
    Bartoloni A, Pizza M, Gross R, Perugini M, Arico B, Domenighini M, Rappuoli R.
    Tokai J Exp Clin Med; 1988 Feb 07; 13 Suppl():217-22. PubMed ID: 2483870
    [Abstract] [Full Text] [Related]

  • 17. An aerosol challenge model of Bordetella pertussis infection as a potential bioassay for acellular pertussis vaccines.
    Xing DK, Das RG, Williams L, Canthaboo C, Tremmil J, Corbel MJ.
    Vaccine; 1999 Feb 12; 17(6):565-76. PubMed ID: 10075163
    [Abstract] [Full Text] [Related]

  • 18. Bordetella Pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performance.
    Dorji D, Mooi F, Yantorno O, Deora R, Graham RM, Mukkur TK.
    Med Microbiol Immunol; 2018 Feb 12; 207(1):3-26. PubMed ID: 29164393
    [Abstract] [Full Text] [Related]

  • 19. Protection of mice inoculated with purified pertussis toxin and filamentous haemagglutinin against intracerebral challenge with live Bordetella pertussis.
    Gupta RK, Saxena SN, Sharma SB, Ahuja S.
    Vaccine; 1990 Jun 12; 8(3):289. PubMed ID: 2363304
    [No Abstract] [Full Text] [Related]

  • 20. Characteristics and potency of an acellular pertussis vaccine composed of pertussis toxin, filamentous hemagglutinin, and pertactin.
    Sheu GC, Wo YY, Yao SM, Chou FY, Hsu TC, Ju CL, Cheng Y, Chang SN, Lu CH.
    J Microbiol Immunol Infect; 2001 Dec 12; 34(4):243-51. PubMed ID: 11825003
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.